All funding news

Biotech funding news

21 recent Biotech rounds across our tracked sources.

安澜德健 logo
🇨🇳

安澜德健

Biotech

安澜德健 develops biotech solutions for healthcare applications in China.

$14MSeries A
Investor undisclosed
A $14M Series A for a China-focused biotech in mid-2026 suggests the domestic healthcare market is still pulling capital, but the round size and lack of named tier-1 investors hints at either a niche therapeutic focus or execution risk that's keeping valuations modest. If you're building adjacent biotech infrastructure (diagnostics, manufacturing, regulatory consulting), watch whether Chinese founders are now raising domestically vs. seeking Singapore/US capital—that shift would signal real confidence in local funding ecosystems.
思昇科技 logo
🇨🇳

思昇科技

Brain-Computer Interface

思昇科技 develops CNS drugs and ultrasonic brain-computer interface technology for neurological applications.

UndisclosedSeed+
Investor undisclosed
思昇科技 logo
🇨🇳

思昇科技

Brain-Computer Interface

思昇科技 develops CNS drugs and ultrasonic brain-computer interface technology for neurological applications.

Undisclosed
Investor undisclosed
微灵医疗 logo
🇨🇳

微灵医疗

Brain-Computer Interface

微灵医疗 develops brain-computer interface technology to restore neural function and communication for patients with neurological conditions.

$14M
Investor undisclosed
A $14M Series A for a Chinese BCI company signals that neural interface hardware is moving past pure research into clinical validation—this is the stage where you need regulatory pathway clarity and animal/early human data. If you're building in adjacent neurotech (neural recording, signal processing, or clinical software), watch whether they're pursuing NMPA approval first or hedging with international trials; that choice telegraphs how fast the Chinese regulatory environment is actually moving for invasive devices.
K2 Therapeutics logo
🇸🇬K2 TherapeuticsOncology, Cell Therapy

K2 Therapeutics develops antibody-drug conjugates and T-cell engagers for cancer treatment, sourcing drug candidates globally.

$50MSeed
M
MPM BioImpact
A $50M seed for a Singapore-based biotech is unusually large and signals that deep-tech oncology—especially cell therapy and ADCs—is attracting patient capital willing to fund longer timelines. If you're building in adjacent biotech (diagnostics, manufacturing, data tools), this validates that investors are still writing big checks for hard science, not just AI/software plays.
Infinimmune logo
InfinimmuneImmunotherapy

Infinimmune develops engineered T cell immunotherapies to treat cancer and autoimmune diseases.

$75MSeries A
Investor undisclosed
A $75M Series A for cell therapy in 2026 signals that engineered T cell platforms are still attracting serious capital despite the category's clinical setbacks—likely because this round is probably funding late-stage manufacturing scale and Phase 2 data generation, not early discovery. If you're building adjacent biotech infrastructure (manufacturing, cell sourcing, data analytics for patient selection), this validates that the bottleneck isn't investor appetite but execution risk on efficacy and cost.
雅本化学 logo
🇨🇳

雅本化学

CDMO

雅本化学provides contract development and manufacturing services for pharmaceutical companies.

$117.7MStrategic
Investor undisclosed
A $117.7M strategic round for a Chinese CDMO signals that pharma supply chain reshoring/diversification is real enough to justify major capital—likely from a pharma customer or consortium locking in capacity. The company probably uses this to expand manufacturing footprint and de-risk single-geography dependency for Western clients. If you're building biotech infrastructure (lab automation, QA software, supply chain visibility), watch whether Chinese CDMOs start demanding better tooling—that's your wedge.
Xunming Biotech logo
Xunming BiotechBiotech

Xunming Biotech develops biotechnology solutions for research and therapeutic applications.

$100MSeries B
Investor undisclosed
A $100M Series B for a biotech company with vague positioning and undisclosed backers is a yellow flag—either the round details are incomplete, or this is a roll-up of smaller funding tranches. If real, it signals someone believes there's a defensible IP moat in research tools or therapeutics, but without knowing the actual tech or investor quality, it's hard to read whether this is genuine category momentum or just capital chasing biotech hype. If you're building adjacent biotech infrastructure, watch whether this company actually ships products or becomes a capital sink.
水赋能电子科技 logo
🇨🇳

水赋能电子科技

Hydrogen Health

水赋能电子科技 develops hydrogen health technology products for wellness consumers globally.

$9.8MAngel
Investor undisclosed
A $9.8M angel round for hydrogen wellness tech in China signals serious capital appetite for alternative health categories in Asia—this isn't a typical biotech play but consumer hardware/supplements with biotech framing. If you're building in adjacent wellness verticals (longevity, biohacking, functional foods), watch whether this company hits distribution through e-commerce or medical channels; that playbook will tell you if the category is real demand or speculative hype.
Quercus Biosolutions logo
Quercus BiosolutionsBiotech

Quercus Biosolutions develops biotech solutions for disease treatment and prevention.

$5MSeed
Investor undisclosed
A $5M seed for a nature-inspired biotech play signals investors are still backing pre-clinical biotech, but the vagueness here is telling—if this were a hot category like synthetic biology or precision fermentation, the narrative would be sharper. Founders in adjacent biotech spaces should watch whether Quercus can actually move from 'sustainable solutions' to a defensible IP moat; right now it reads like a team bet more than a technology bet.
Dash Bio logo
Dash BioBiotech

Dash Bio builds bioinformatics software for researchers and biotech companies to analyze and visualize genomic data.

$30MSeries A
Investor undisclosed
A $30M Series A for genomics visualization software signals that biotech tooling—especially the unglamorous but essential layer between raw data and insights—is finally getting serious capital. At this stage and size, Dash Bio is likely hiring hard on product/eng and building out enterprise sales motion, which means the market for "boring" infrastructure is maturing past the DIY phase. If you're building any kind of data platform for life sciences, this validates that customers will pay for tools that save researchers weeks of work, even if it's not a direct therapeutic.
盈创未来 logo
🇨🇳

盈创未来

Medical Devices

盈创未来 builds surgical navigation systems for intraoperative guidance and positioning during procedures.

$1.4MAngel
Investor undisclosed
A $1.4M angel for surgical navigation in China signals the market is finally willing to fund hardware-heavy medtech there—previously a VC graveyard due to reimbursement friction. They're likely burning this on regulatory clearance and hospital pilot deployments, not R&D. If you're building any OR-adjacent software (scheduling, complication prediction, post-op analytics), watch whether Chinese hospitals actually adopt this; it's the canary for whether the whole surgical-tech stack can get traction in that market.
Arboreal Bioinnovations logo
🇮🇳Arboreal BioinnovationsFood & Nutraceutical Ingredients

Arboreal Bioinnovations develops proprietary functional ingredients like plant proteins and natural sweeteners for food and beverage brands.

$28KSeries A
E
EAAA Alternatives
OR
Xeltis logo
XeltisMedical Devices

Xeltis develops regenerative medical devices using bioresorbable technology for cardiovascular and orthopedic applications.

$22.3M
Investor undisclosed
A $22.3M raise for a bioresorbable device company signals that investors are still backing the long clinical pathway for regen med—but only if you have differentiated IP and a clear path to first indication. If you're in adjacent biotech, this matters because it shows the bar for Series A/B in this space is execution clarity (likely they're de-risking a specific clinical endpoint), not just platform hype. Watch whether they're burning this on manufacturing scale or clinical trials—that tells you if the market is actually ready to fund the manufacturing risk.
昌郁医药 logo
🇨🇳

昌郁医药

Pharmaceuticals

昌郁医药 develops XG005, a novel pain treatment drug candidate advancing through clinical trials.

$35MSeries D
倚
倚锋资本
高嘉R
A $35M Series D for a pain drug in late-stage trials signals China's biotech investors are still backing clinical-stage assets despite global funding headwinds—but the bar is clearly higher (this is a smaller round than typical for this stage in 2024-25). If you're building in adjacent therapeutic areas or med-tech, watch whether XG005 clears Phase 3: Chinese pharma VCs are rotating capital toward companies with near-term regulatory wins, not just promising preclinics.
CORE Biomedicine logo
CORE BiomedicineBiotech

CORE Biomedicine develops biotech solutions for disease treatment and research applications.

$21MSeries A
Investor undisclosed
A $21M Series A for a biotech company in 2026 suggests the market is still funding platform plays in drug discovery/research tools, but the relatively modest check size hints investors are being selective—likely betting on CORE's specific technical moat rather than category tailwinds. If you're building in adjacent biotech infrastructure (lab automation, data platforms, regulatory software), this signals that generalist capital is still available, but you'll need a defensible technical angle, not just a problem statement.
Changyu Pharma logo
🇨🇳Changyu PharmaPharmaceuticals

Changyu Pharma develops pharmaceutical products for the Chinese market.

$35MSeries D
Investor undisclosed
A $35M Series D for a China-focused pharma company in mid-2026 suggests domestic biotech is still attracting late-stage capital despite macro headwinds—but the undisclosed investor list is a yellow flag that this might be government-backed or a down round. If you're building biotech infrastructure (manufacturing, regulatory, supply chain), watch whether Changyu's next moves are geographic expansion or pure domestic consolidation; that'll tell you if Chinese pharma is ready to compete globally or just optimizing for domestic margin.
Tikva Allocell logo
🇸🇬Tikva AllocellCell Therapy

Tikva Allocell develops off-the-shelf allogeneic cell therapies targeting B7-H3+ solid tumors using engineered EBV-specific T cells.

$8MSeries A
K
Kantharos Capital
An $8M Series A for an allogeneic cell therapy in Singapore signals that off-the-shelf CAR-T is finally moving past the hype—this company is betting on EBV-specific T cells as a manufacturing shortcut to avoid the personalization bottleneck that's killed other programs. If you're building in adjacent cell therapy or immunotherapy, watch whether they can actually scale manufacturing; if they crack it, the playbook shifts from patient-specific to platform-based, which changes unit economics entirely.
N-Zyme Biomedical logo
N-Zyme BiomedicalBiotech

N-Zyme Biomedical develops enzyme-based biomedical solutions for therapeutic applications.

$4.6MSeries A
Investor undisclosed
A $4.6M Series A for an enzyme-therapy company signals biotech investors are still backing platform plays with narrow initial indications—this isn't a hot category moment, but rather patient capital betting on technical moats. They're likely funding manufacturing scale-up and IND-enabling studies, which means 18-24 months to clinical data. If you're in synthetic biology or protein engineering, watch whether N-Zyme's go-to-market strategy (licensing vs. direct development) becomes the template for other enzyme platforms.
果核 logo
🇨🇳

果核

Dental Tech

果核 builds intelligent orthodontic equipment for dental clinics using digital processing and manufacturing technology.

UndisclosedPre-A
Investor undisclosed
Changzhou Henghé logo
🇨🇳Changzhou HenghéMedical Devices

Changzhou Henghé develops surgical smoke evacuation and abdominal pressure management devices for precision surgery.

UndisclosedAngel
Investor undisclosed